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ABSTRACT 
 
Purpose: The purpose of this study was to determine the effects of supplementation with a water-soluble 
cinnamon extract (Cinnulin PF®)
 on body composition and features of the metabolic syndrome. Methods: 
Twenty-two subjects with prediabetes and the metabolic syndrome (mean ± SD: age, BMI, systolic blood 
pressure [SBP], fasting blood glucose [FBG]: 46.0 ± 9.7 y; 33.2 ± 9.3 kg/m
2; 133 ± 17 mm Hg; 114.3 ± 11.6 
mg/dL) were randomly assigned to supplement their diet with either Cinnulin PF® (500 mg/d) or a placebo for 
12-weeks. Main outcome measures were changes in FBG, SBP, and body composition measured after 12-weeks 
of supplementation. The primary statistical analyses consisted of two factor (group x time), repeated-measures 
ANOVA for between group differences over time. In all analyses, an intent-to-treat approach was used and 
significance was accepted at P<0.05. Results: Subjects in the Cinnulin PF® group had significant decreases in 
FBG (-8.4%: 116.3 ± 12.8 mg/dL [pre] to 106.5 ± 20.1 mg/dL [post], p<0.01), SBP (-3.8%: 133 ± 14 mm Hg 
[pre] to 128 ± 18 mm Hg [post], p<0.001), and increases in lean mass (+1.1%: 53.7 ± 11.8 kg [pre] to 54.3 ± 
11.8 kg [post], p<0.002) compared with the placebo group. Additionally, within-group analyses uncovered 
small, but statistically significant decreases in body fat (-0.7%: 37.9 ± 9.2 % [pre] to 37.2 ± 8.9 % [post], 
p<0.02) in the Cinnulin PF® group. No significant changes in clinical blood chemistries were observed between 
groups over time. Conclusions: These data support the efficacy of Cinnulin PF® supplementation on reducing 
FBG and SBP, and improving body composition in men and women with the metabolic syndrome and suggest 
that this naturally-occurring spice can reduce risk factors associated with diabetes and cardiovascular diseases.  
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INTRODUCTION 
 
A number of spices and herbs have a long history of 
traditional use in treating elevated blood sugar levels 
1. One such compound that has recently been the 
subject of intense research is cinnamon, a compound 
granted GRAS (Generally Recognized As Safe) 
status by the United States Food and Drug 
Administration. The beneficial effects of cinnamon 
on glucose control appear to be in part due to doubly-
linked polyphenol type-A compounds 
2. Over the past 
two decades, in vitro and in vivo data have been 
accumulating which support the role of cinnamon on 
glycemic control. For example, Jarvill-Taylor et al. 
3 
reported that cinnamon stimulated glucose uptake, 
glycogen synthesis, and activated glycogen synthase 
in 3T3-L1 adipocytes. In rats, cinnamon enhanced 
glucose uptake by enhancing insulin-stimulated 
tyrosine phosphorylation of insulin receptor-β, 
insulin receptor substrate-1, and phosphatidylinositol 
3-kinase in a dose-dependent fashion 
4,5. To date, 
human studies demonstrating beneficial effects of 
cinnamon supplementation on glucose regulation 
have studied subjects with type II diabetes 
6,7. In a 
dose-response study, Khan et al. 
6 reported that 40-
days of supplementation with 1, 3, or 6 grams of 
whole cinnamon per day resulted in dose-dependent 
decreases in fasting blood glucose (FBG), and 
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improvements in blood lipid profiles, in subjects with 
poorly controlled diabetes and dyslipidemia. More 
recently, Mang et al. 
7 reported a 10.3% decrease in 
FBG after four months of supplementation with a 
purified aqueous cinnamon extract. Thus, the effects 
of cinnamon and cinnamon extract on improving 
insulin signaling and glucose regulation in type II 
diabetics appear promising.  
 
Several studies have linked diabetes to obesity-
induced insulin resistance 
8. In this regard, an 
estimated 41 million people in the U.S. have 
prediabetes, a condition of elevated fasting blood 
sugar that is strongly associated with hyperlipidemias 
and cardiovascular disease 
9. When considered 
collectively, elevated blood sugar, hyperlipidemia, 
hypertension, and obesity constitute a potentially 
dangerous physiological condition known as 
“Syndrome X” or the Metabolic Syndrome. The 
National Cholesterol Education Program has 
established the current criteria for the metabolic 
syndrome as ≥ three of the following: 1) waist 
circumference > 102 cm (40 inches) for men or > 88 
cm (35 inches) for women; 2) a fasting total serum 
triacylglycerol concentration of > 1.7 mmol/L (150 
mg/dL); 3) a fasting HDL cholesterol concentration < 
1.0 mmol/L (40 mg/dL) for men or < 1.2 mmol/L (50 
mg/dL) for women; 4) a fasting glucose > 6.1 
mmol/L (110 mg/dL); or blood pressure > 130 mm 
Hg (systolic) and/or 85 mm Hg (diastolic) and/or the 
use of antihypertensive medication 
10. In addition to 
the positive effects of cinnamon on glucose 
regulation, there are data which support the beneficial 
effects of cinnamon on blood pressure 
11 and 
hyperlipidemias 
6. Though limited, the existing 
evidence suggests a potential role for cinnamon as a 
positive influence on several features of the 
metabolic syndrome.  
 
The purpose of this placebo-controlled, double-blind 
study was to determine the effects of supplementation 
with a specific water-soluble cinnamon extract 
(Cinnulin PF®) on FBG and body composition in 
prediabetic men and women with features of the 
metabolic syndrome. In addition, to assess the safety 
profile of this compound we measured changes in 
standard markers of health (e.g., resting heart rate and 
blood pressure) and clinical chemistry panels of 
serum and plasma. Several markers of plasma 
antioxidant status as well as long-term glucose 
control and insulin sensitivity were also measured, 
and will be addressed in a separate manuscript (in 
preparation).  
 
 
RESEARCH DESIGN AND METHODS 
 
Experimental approach. This study was a 
randomized, placebo-controlled, double-blind clinical 
trial with two parallel groups. Serum chemistry, body 
weight, and body composition were measured at 
baseline and at the end of the 12-week 
supplementation period. Subjects also completed 3-
day food records and had measurements of their 
systolic and diastolic blood pressures during pre 
(week 0), mid (week 6), and post (week 12) testing. 
Figure 1 presents the flow of participants through the 
study.  
    
Subjects.  Subjects were recruited from northeastern 
Ohio, a typical suburban region, by word of mouth 
and posted announcements. Thirty potential 
participants aged 30-60 years were interviewed by 
telephone. Of these, 22 were invited for a preliminary 
screening consisting of height, weight, blood 
pressure, and a fasting blood sample. Subjects were 
required to have FBG between 100 mg/dL (5.6 
mmol/L) and 125 mg/dL (6.9 mmol/L), have normal 
values for liver and kidney function tests, and be 
willing to maintain their usual dietary and physical 
activity habits. Subjects were excluded from the 
study if they had a body mass index (BMI) > 40 
kg/m
2, thyroid disease, hypogonadism, a history of 
musculoskeletal, autoimmune, or neurologic disease, 
or if they were currently taking thyroid, 
hyperlipidemic, hypoglycemic, anti-hypertensive, or 
anti-coagulant medications. Prior to obtaining written 
informed consent from each subject, an institutional 
review board (IntegReview Inc, Austin, TX) 
approved the experimental protocol. All procedures 
in the study were in accord with ethical standards set 
forth in the Helsinki Declaration of 1975, as revised 
in 1983. 
 
Supplementation.  After matching for age, FBG, 
SBP, and habitual physical activity levels, subjects 
were randomly assigned to a Cinnulin PF® (n=12) or 
placebo (n=10) group. Each subject was instructed to 
take two capsules (250 mg) of their respective 
supplement twice per day (with breakfast and 
dinner). According to the manufacturer, 500 mg of 
Cinnulin PF® is equivalent to approximately 10 g of 
whole cinnamon powder (i.e., 20:1 extract), and 
contains at least 1% doubly-linked polyphenol type-
A polymers (considered to be the bioactive 
component). Supplements were prepared in a 2-piece 
hard shell capsule form and packaged in coded 
generic containers for double-blind administration by 
Integrity Nutraceuticals International (Sarasota, FL). 
Medical monitoring and compliance to the  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
 
47
 
Persons expressing interest in study  
(n = 30) 
Screened for participation and  
randomly assigned 
(n = 22) 
Placebo group 
(n = 10) 
Cinnulin group 
(n = 12) 
Withdrew 
(n = 0) 
Withdrew 
(n = 1 @ wk 6) 
Analyzed 
(n = 10) 
*Analyzed 
(n = 12) 
 
Figure 1. Study Flow Chart. *One subject in the Cinnulin group withdrew at week 6 due to pregnancy. For this subject, we 
imputed her remaining data using the last-observation-carried-forward method (i.e., week 0 values were used at week 6 and 
week 12). 
 
 
supplementation protocol was supervised by a 
research technician who contacted the subjects on a 
weekly basis. Each subject was required to return the 
original bottle of their respective supplement for 
capsule counts during mid (week 6) and post (week 
12) testing.  
 
Heart rate and blood pressure.  All subjects reported 
to the laboratory after a 12-hour fast and at least 48-
hours after participating in intense physical activity. 
Following ten minutes of seated rest, subjects’ heart 
rate and blood pressure were determined by palpation 
of the radial artery and aneroid sphygmomanometry, 
respectively. The same technician performed all 
measurements using standard procedures.  
 
Blood collection and analyses.  Immediately 
following blood pressure readings, 
approximately 20 mL of blood was drawn with 
stasis via venipuncture of an antecubital vein. All 
blood samples were taken in the morning at 
approximately the same time of day to minimize 
diurnal variation, and subjects used their baseline 
diet records to standardize their final (evening) 
meal before mid (week 6) and post (week 12) 
testing.  
 
Blood samples were harvested into tubes with 
and without EDTA, centrifuged (Drucker Model 
614, Philipsburg, PA) at room temperature for 15 
minutes at 1200 x g to obtain plasma and serum, 
and immediately placed into two aliquots. One 
aliquot was immediately analyzed for a 21-item 
clinical chemistry profile (Hitachi D2400, Roche 
Diagnostics, Germany) by a certified clinical 
laboratory (Laboratory Corporation of America, 
Dublin, OH). This profile consisted of a 
comprehensive metabolic panel (glucose, BUN, 
creatinine, sodium, potassium, chloride, carbon 
dioxide, calcium, total protein, albumin, 
globulin, total bilirubin, alkaline phosphatase,  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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AST [SGOT], and ALT [SGPT]) as well as a 
lipid profile (total cholesterol, HDL-C, LDL-C, 
VLDL-C, triacylglycerol). 
 
Body composition.  Body weight was measured using 
a calibrated digital A&D™ Medical Scale (Model 
UC-300, Milpitas, CA), standing height was 
measured using a wall-mounted stadiometer (Seca 
Model 216, Hanover, MD) and body composition 
was measured with dual-energy x-ray absorptiometry 
(GE Lunar DPX Pro, Madison, WI). All dual-energy 
x-ray absorptiometry (DEXA) scans were performed 
by the same technician and analyzed according to 
software (enCORE version 7.53.002, 2003) provided 
by the manufacturer. Briefly, subjects were 
positioned in the scanner according to standard 
procedures and remained motionless for 
approximately 15 minutes during scanning. DEXA 
segments for the arms, legs, and trunk were 
subsequently obtained using standard anatomical 
landmarks. Using a three-compartment model, 
DEXA calculates fat mass, lean mass, and bone mass. 
Percent fat was calculated by dividing fat mass by the 
total scanned mass. Quality control calibration 
procedures were performed prior to all scans using a 
calibration block provided by the manufacturer. Prior 
to this study, we determined test-retest reliability for 
repeated measurements of lean mass, bone mineral 
content, and fat mass with this DEXA via intra-class 
correlation coefficients. All values were > 0.98.  
 
Diet and physical activity. As mentioned previously, 
this study used a free-living design where subjects 
were advised to maintain their normal diet during the 
study. To verify this, subjects completed 3-d food 
records (which included two weekdays and one 
weekend day) during baseline testing, week 6, and 
week 12. All food records were analyzed by a 
licensed, registered dietitian using commercially 
available software (NutriBase IV Clinical Edition, 
AZ). To enhance accuracy of the food records, all 
subjects received instruction during baseline testing 
on how to accurately estimate portion sizes. This 
counseling was reinforced during each visit to the 
laboratory. No dietary supplements were allowed 
with the exception of standard strength 
multivitamins. Subjects were also advised to maintain 
their current level of habitual physical activity 
throughout the study. Physical activity levels were 
measured with the Framingham Physical Activity 
Index 
(12) during baseline testing, week 6, and week 
12. 
 
Statistical analyses.  Statistical analyses were 
conducted using Statistica version 7.1 (Stat Soft Inc., 
Tulsa, OK). Differences between groups at baseline 
were analyzed with independent t-tests and chi-
square tests. Separate 2 x 2 or 2 x 3 (Group x Time) 
univariate ANOVA with repeated measures on the 
last factor were used to analyze between group 
differences over time. Since a drop-out did occur in 
this study, intent-to-treat analyses (ITT) were 
performed, using the last-observation-carried-forward 
method. In an ITT approach, all randomized subject's 
data are included in the data analyses, regardless of 
whether they complete the trial or are compliant with 
the procedures. In contrast, most studies on dietary 
supplements use a “per protocol” analysis and 
exclude non-compliant subjects or subjects who 
drop-out. Although a discussion of ITT analyses is 
beyond the scope of this paper, many researchers 
consider ITT to be the preferred method of data 
analysis in clinical efficacy studies as it is less prone 
to bias. Readers are referred to Hollis et al. 
(13) and 
Moher et al. 
(14) for a more thorough overview of ITT 
analyses. When a significant interaction was 
observed, Fisher’s Least Significant Differences 
(LSD) post-hoc test was performed. When the 
interaction term was “marginally significant” (i.e., 
0.05 < P < 0.10), changes from day 0 to day 84 
within treatment groups were assessed with a paired 
t-test. Differences were considered statistically 
significant at P < 0.05. Power analysis for this 2 x 3 
design indicated that a sample size of 10-15 subjects 
per group yields moderate power (≥ 0.80) for delta 
values of 0.75 to 1.25.  
 
RESULTS 
 
Table 1 presents baseline characteristics of the 
subjects. Both groups met the criteria of the Adult 
Treatment Panel III of the National Cholesterol 
Education Program for having the metabolic 
syndrome 
(10). Specifically, both groups had FBG > 
110 mg/dL (Cinnulin: 116 ± 13, Placebo: 112 ± 10), 
systolic BP > 130 mm Hg (Cinnulin: 133 ± 14, 
Placebo: 133 ± 22) and triacylglycerol > 150 mg/dL 
(Cinnulin: 166 ± 142, Placebo: 165 ± 107). There 
were no significant differences in general, metabolic, 
or dietary characteristics between groups at baseline 
(Table 1). 
 
Supplementation Compliance and Adverse Events. 
Compliance to the supplementation regimen was 
defined as the number of capsules actually taken by 
each subject divided by the number of capsules that 
should have been taken over the course of the study. 
Excluding one drop-out in the Cinnulin group,  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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       Table 1. Baseline Characteristics of Subjects 
  Placebo (n=10)  Cinnulin (n=12)  P-value 
General      
   Sex (M/F)  3/7  8/4  0.15 
   Age (y)  45.6 ± 11.1  46.3 ± 8.8  0.88 
   Weight (kg)  89.3 ± 30.6  93.1 ± 18.1  0.72 
   BMI (kg/m
2)  34.4 ± 12.6  32.3 ± 5.7  0.61 
   Body Fat (%)  43.8 ± 8.0  37.9 ± 9.2  0.13 
   Lean Mass (kg)  43.9 ± 11.1  53.7 ± 11.8  0.06 
        
Metabolic      
   Systolic Blood Pressure (mm Hg)  133 ± 22  133 ± 14  0.94 
   Diastolic Blood Pressure (mm Hg)  83 ± 14  83 ± 6  0.94 
   Glucose (mg/dL)  112 ± 10  116 ± 13  0.40 
   Total Cholesterol (mg/dL)  192 ± 49  185 ± 44  0.72 
   LDL Cholesterol (mg/dL)  105 ± 52  107 ± 36  0.90 
   VLDL Cholesterol (mg/dL)  33 ± 21  25 ± 9  0.28 
   HDL Cholesterol (mg/dL)  55 ± 14  50 ± 13  0.36 
   Triacylglycerol (mg/dL)  165 ± 107  166 ± 142  0.99 
      
Dietary      
   Kcals/day  1706 ± 427  1741 ± 551  0.87 
   % Carbohydrate  46 ± 13  43 ± 12  0.59 
   % Fat  33 ± 9  33 ± 10  0.98 
   % Protein  20 ± 11  23 ± 7  0.38 
   Fiber (grams/d)  14 ± 7  16 ± 8  0.42 
 
        Data are expressed as group means ± SD. P-values were calculated from independent t-tests for all  
        variables except sex (where a chi -square test was used). No significant differences were noted between  
        groups, although there was a trend for greater lean mass in the Cinnulin group (P<0.06). To convert  
        glucose from mg/dL into mmol/L multiply by 0.0555; to convert cholesterol (total, LDL-C, VLDL-C and 
        HDL-C) from mg/dL into mmol/L multiply by 0.0259; to convert triacylglycerol from mg/dL into  
        mmol/L multiply by 0.0113. 
 
 
compliance was > 97% in both groups. Adverse 
events were based on spontaneous reporting by 
subjects as well as open-ended inquiries by members 
of the research staff. No adverse events were reported 
during the study in either group.  
 
HR and BP.  After 12-weeks, subjects in the 
Cinnulin group decreased their SBP by 3.8% (from 
133 ± 14 mm Hg [pre] to 128 ± 18 mm Hg [post], 
P<0.001) compared to subjects in the Placebo group 
(from 133 ± 22 mm Hg [pre] to 142 ± 20 mm Hg 
[post]). No between or within-group changes in 
diastolic blood pressure (Cinnulin: from 83 ± 6 mm  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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Hg [pre] to 84 ± 9 mm Hg [post]; Placebo: from 83 ± 
14 mm Hg [pre] to 86 ± 12 mm Hg [post], P<0.32) or 
HR (Cinnulin: from 69 ± 14 beats/min [pre] to 69 ± 
12 beats/min [post]; Placebo: from 71 ± 15 beats/min 
[pre] to 74 ± 8 beats/min [post], P<0.73) were noted 
in either group. 
 
Blood Chemistry.  Figure 2 presents changes in FBG 
during the study. Subjects in the Cinnulin group had 
significant decreases in FBG (-8.4%: from 116.3 ± 
12.8 mg/dL [pre] to 106.5 ± 20.1 mg/dL [post], 
P<0.01) compared to subjects in the Placebo group 
(from 112.0 ± 10.0 mg/dL [pre] to 113.1 ± 14.7 
mg/dL [post]). No other between group effects were 
noted for BUN, creatinine, bilirubin, alkaline 
phosphatase, AST (SGOT), ALT (SGPT), sodium, 
potassium, chloride, calcium, albumin, globulin, CO2, 
total protein, total cholesterol, HDL-C, LDL-C, 
VLDL-C, or triglycerides and all values remained 
within normal clinical limits (selected hematological 
variables are shown in Table 2).  
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Figure 2. Significant Changes in Primary Endpoints During the 
Study.  Data are expressed as change scores (week 12 – week 0). 
Values represent group means ± SE. P-values were calculated 
from repeated measures (group x time) ANOVA, except for % fat 
where a dependent t-test was used following a marginally 
significant (P<0.06) interaction term. 
  
 
Body Composition. Figure 2 presents changes in 
body composition during the study. Subjects in the 
Cinnulin group increased their lean mass by 1.1% 
(from 53.7 ± 11.8 kg [pre] to 54.3 ± 11.8 kg [post], 
P<0.002), and decreased their body fat by 0.7% (from 
37.9 ± 9.2% [pre] to 37.2 ± 8.9% [post]; within-group 
analysis, P<0.02). No changes in lean mass (from 
43.9 ± 11.1 kg [pre] to 43.1 ± 10.9 kg [post]) or fat 
mass (from 43.8 ± 8.0% [pre] to 44.2 ± 9.0% [post]) 
were noted in the Placebo group. Because the 
baseline value for lean mass was marginally 
significant (P<0.06), we also performed an 
ANCOVA using week 0 lean mass as the covariate. 
Results confirmed that lean mass at week-12 was 
significantly greater in the Cinnulin group (P<0.004).  
 
Diet and Physical Activity.  Table 3 presents totals 
for three-day dietary intake obtained during the 
study. No changes in total daily energy, 
macronutrient, or fluid intake were noted during the 
study, although there was a trend for subjects in the 
Cinnulin group to consume more total energy 
(P<0.07). Follow-up testing for within-group changes 
(via dependent t-test) indicated subjects in the 
Cinnulin group ingested significantly more total 
energy during week-12 (P<0.04). Due to errors in 
data recording and processing, our quantitative 
assessment of physical activity (via the Framingham 
Physical Activity Index) could not be accurately 
completed. However, during mid and post-testing, no 
subject reported any changes in habitual activity 
levels during the course of the study.  
 
DISCUSSION 
 
Our findings indicate that consuming 500 mg/day of 
a specific aqueous extract of cinnamon (Cinnulin 
PF®) for 12-weeks leads to significant improvements 
in several features of the metabolic syndrome (i.e., 
fasting blood sugar, systolic blood pressure, and body 
composition). Because of the relationship between 
the metabolic syndrome and cardiovascular disease, 
these results, if confirmed by other research groups, 
have important implications for public health. To our 
knowledge, this is the first study in humans that used 
cinnamon powder standardized to what is currently 
considered to be the bioactive component (e.g. 
doubly-linked polyphenol type-A polymers) 
2. This is 
important as Cinnamomum cassia is a large genus, 
and there may be differences in bioactivity due to 
methods of preparation, extraction, and geographical 
source.  
 
The observed reduction in FBG in our study is less 
than that of Khan et al. 
6 and similar in magnitude to 
Mang et al. 
7. Khan et al. studied the effects of 1, 3, 
and 6 g/d of whole cinnamon powder on FBG and 
serum lipids in 60 people with poorly controlled type 
2 diabetes from Pakistan. After 40 days of 
supplementation, FBG decreased by 18-29%, 
cholesterol decreased by 12-26%, LDL cholesterol 
decreased by 7-27%, and triacylglycerol decreased by 
23-30%. More recently, Mang et al. supplemented 79 
people with type 2 diabetes from Germany with 3 g/d 
cinnamon powder or a placebo for four months.  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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    Table 2. Selected Hematological Responses to Supplementation. 
 
 Placebo 
(n=10) 
Cinnulin 
(n=12) 
P-value  
(GxT) 
Reference  
Interval 
BUN:Creatinine     0.21 8-27 
   Pre  16 ± 5  16 ± 4    
   Mid  19 ± 5  18 ± 4    
   Post  16 ± 4  18 ± 4    
Bilirubin (mg/dL)      0.50  0.1-1.2 
   Pre  0.5 ± 0.1  0.7 ± 0.3    
   Mid  0.5 ± 0.1  0.8 ± 0.4    
   Post  0.5 ± 0.2  0.6 ± 0.3    
Alkaline Phosphatase 
(IU/L)      
0.12 
 
25-150 
   Pre  77 ± 17  65 ± 14    
   Mid  71 ± 16  67 ± 16    
   Post  67 ± 16  60 ± 11    
Aspartate 
aminotransferase (IU/L)      
0.94 
 
0-40 
   Pre  29 ± 15  29 ± 17    
   Mid  26 ± 11  26 ± 13    
   Post   25 ± 8  24 ± 8    
Alanine 
aminotransferase (IU/L)      
0.59 
 
0-40 
   Pre  30 ± 16  38 ± 28    
   Mid  30 ± 17  34 ± 25    
   Post  28 ± 14  32 ± 22    
Cholesterol (mg/dL)      0.81  100-199 
   Pre  192 ± 49  185 ± 44    
   Mid  191 ± 50  190 ± 36    
   Post  193 ± 47  190 ± 33    
Triacylglycerol (mg/dL)       0.75  0-149 
   Pre  165 ± 107  166 ± 142    
   Mid  172 ± 111  152 ± 76    
   Post  195 ± 146  162 ± 132    
HDL (mg/dL)      0.73  40-59 
   Pre  55 ± 14  50 ± 13    
   Mid  54 ± 15  48 ± 13    
   Post  55 ± 16  50 ± 13    
VLDL (mg/dL)      0.31  5-40 
   Pre  33 ± 21  25 ± 9    
   Mid  34 ± 21  30 ± 15    
   Post  36 ± 22  25 ± 11    
LDL (mg/dL)      0.44  0-99 
   Pre  105 ± 52  107 ± 36    
   Mid  102 ± 57  112 ± 34    
   Post  99 ± 54  111 ± 29    
 
    Data are expressed as group means ± SD. P-values were calculated from two-way (group x time)  
    ANOVA. No significant differences were noted between groups over time. To convert bilirubin  
    from mg/dL into mmol/L multiply by 17.1; to convert cholesterol (total, LDL-C, VLDL-C and  
    HDL-C) from mg/dL into mmol/L multiply by 0.0259; to convert triacylglycerol from mg/dL  
    into mmol/L multiply by 0.0113. 
 
Although no changes in blood lipids or glycosylated 
hemoglobin (HBA1c) were noted, researchers did find 
a 10.3% reduction in FBG. In both studies (as well as 
ours), no adverse events were reported by subjects 
taking cinnamon, and subjects with the poorest 
glycemic control appeared to benefit the most. In 
agreement with Mang et al. 
7, but in contrast to Khan 
et al. 
6, we found no changes in blood lipids from 
cinnamon supplementation. We suspect this is 
because: 1) our subjects’ lipid levels were not  Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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abnormal, and 2) the observed decrease in FBG (-
8.4%) was not large enough to affect lipid 
metabolism. Regardless, given the strong effects of 
cinnamon on insulin signaling in animal models, 
future studies in humans should consider examining 
changes in more sensitive predictors of 
cardiovascular disease risk (i.e., various lipoprotein 
subfractions). The statistically significant decrease in 
systolic SBP observed in this study (from 133 to 129 
mm Hg, P<0.001) echoes findings from Preuss et al. 
11 in spontaneously hypertensive rats, and was 
clinically meaningful in that values > 130 mm Hg are 
considered to be a risk factor for the metabolic 
syndrome 
10. 
 
Not all studies have found beneficial effects of 
cinnamon on FBG. Vanschoonbeek et al. 
15 reported 
no effect of 1.5 g/d x 6 wk cinnamon powder on 
indices of glycemic control (FBG, insulin, oral 
glucose tolerance test [OGTT], HBA1c, insulin 
sensitivity, and insulin resistance) or blood lipids in 
25 postmenopausal women from the Netherlands. 
That study is different from that of Khan et al. 
6 and 
Mang et al. 
7 (as well as the current study) in that 
only postmenopausal females were included as 
subjects. Whether differences in hormonal milieu 
affect the potential interaction between cinnamon 
supplementation and glucose control is unknown at 
this time.  
 
A unique finding in our study is the small, but 
statistically significant improvement in body 
composition from Cinnulin PF® supplementation. 
Previous research has shown cinnamon extracts can 
activate glycogen synthase, stimulate glucose uptake, 
and inhibit glycogen synthase kinase 3β 
1-3,16. 
Collectively, these effects, combined with the slight 
increase in total energy intake, may have led to the 
observed increases in lean mass in the Cinnulin PF® 
group. Cinnamon also has antioxidant effects 
17-19 that 
may favorably impact hormone signaling via 
adipokine cross-talk. For example, Chrysohoou et al. 
19 recently reported an inverse relationship between 
body fat and antioxidant capacity, even after 
controlling for smoking, physical activity patterns, 
dietary habits, blood pressure, glucose levels, and 
lipid concentrations. It is therefore possible that the 
observed improvements in FBG, as well as plasma 
antioxidant status (e.g., FRAP, MDA, and SH – 
manuscript in preparation) are responsible, at least in 
part, for cinnamon’s beneficial effects on body 
composition and features of the metabolic syndrome.  
 
Summary. In many parts of the civilized world, 
physical inactivity and poor dietary habits are 
increasing rates of prediabetes, obesity, and the 
development of cardiovascular diseases. Current 
estimates are that the metabolic syndrome affects 
over 26% of adults, or over 50 million Americans, 
and that it increases the risk for atherosclerotic 
cardiovascular disease up to 3-fold, and the risk for 
type 2 diabetes up to 5-fold 
(9). Based on the results of 
this study, Cinnulin PF® may play a beneficial role 
in ameliorating the effects of several chronic diseases 
of modernization. Although speculative, because 
subjects in this study were not required to follow any 
specific diet or exercise program, it is possible that 
combining Cinnulin PF® with a nutrient-dense diet 
and/or a regular exercise program may lead to even 
greater health benefits. These preliminary data 
support the efficacy of Cinnulin PF® 
supplementation on reducing FBG in prediabetic men 
and women. It also appears that this particular water-
soluble cinnamon extract, standardized for 
polyphenolic type-A polymers, can favorably alter 
systolic blood pressure and body composition when 
consumed for at least 12-weeks. Finally, although it 
is acknowledged that we used a relatively small, 
homogeneous sample of subjects, Cinnulin PF® 
appears to be reasonably safe at the dose and duration 
studied. Larger, longer-term multi-center studies are 
necessary to confirm our findings, determine the 
mechanism(s) underpinning the observed 
physiological effects, and delineate any dose-
response effects from this naturally-occurring spice.  
 
Table 3. Three-day Total Dietary Intake of Subjects 
 
   
Placebo 
(pre) 
 
 
Placebo 
(post) 
 
 
Cinnulin 
(pre) 
 
 
Cinnulin 
(post) 
 
P-value
(GxT) 
 
Total energy 
(kcals/d) 
 
1706 ± 
427 
 
1613 ± 
364 
 
1741 ± 
551 
 
1982 ± 
530 
 
0.07 
Carbohydrate 
(%) 
46 ± 13  46 ± 11  43 ± 12  43 ± 10 0.94 
Fat (%)  33 ± 9  33 ± 8  33 ± 10  35 ± 7  0.70 
Protein (%)  20 ± 11  20 ± 7  23 ± 7  21 ± 7  0.91 
Fluid Intake (oz) 20 ± 10  25 ± 8  24 ± 9  25 ± 9  0.39 
Saturated fat 
(g/d) 
18 ± 10  18 ± 11  16 ± 7  23 ± 13 0.37 
Cholesterol 
(mg/d) 
331 ± 239 280 ± 174  258 ± 
137 
275 ± 
155 
0.26 
Sodium (mg/d) 3402 ± 
1488 
4160 ± 
2098 
4426 ± 
2351 
4419 ± 
1943 
0.58 
Fiber (g/d)  14 ± 7  17 ± 7  16 ± 8  20 ± 11 0.65 
 
Data are expressed as group means ± SD. P-values were 
calculated from repeated measures (group x time) ANOVA. No 
significant differences were noted between groups over time, 
although there was a trend (P<0.07) for subjects in the Cinnulin 
group to ingest more total energy. To convert from kcals into 
Joules (kJ) multiply by 4186; to convert from ounces (oz) into 
milliliters multiply by 29.573. Journal of the International Society of Sports Nutrition. 3(2): 45-53 2006. (www.sportsnutritionsociety.org) 
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